MTOR and prostate cancer: For example, Li et al. [30] found that individuals carrying four adverse genotypes from six mTOR polymorphisms (rs2536, rs1883965, rs1034528, rs17036508, rs3806317, and rs2295080) exhibited a higher susceptibility of developing prostate cancer (adjusted OR = 1.74, 95% CI 1.20-2.51) compared with those with one or zero adverse genotypes.